HC Wainwright Has Optimistic Outlook of JANX Q1 Earnings

Janux Therapeutics, Inc. (NASDAQ:JANX) – Analysts at HC Wainwright raised their Q1 2026 EPS estimates for shares of Janux Therapeutics in a research note issued to investors on Monday, March 2nd. HC Wainwright analyst S. Ramakanth now expects that the company will earn ($0.56) per share for the quarter, up from their previous forecast of ($0.63). HC Wainwright has a “Buy” rating and a $45.00 price target on the stock. The consensus estimate for Janux Therapeutics’ current full-year earnings is ($1.38) per share. HC Wainwright also issued estimates for Janux Therapeutics’ Q2 2026 earnings at ($0.59) EPS, Q3 2026 earnings at ($0.61) EPS, Q4 2026 earnings at ($0.64) EPS, FY2026 earnings at ($2.40) EPS, FY2027 earnings at ($2.97) EPS, FY2028 earnings at ($3.18) EPS, FY2029 earnings at ($1.01) EPS and FY2030 earnings at $1.08 EPS.

Janux Therapeutics (NASDAQ:JANX) last announced its quarterly earnings results on Thursday, February 26th. The company reported ($0.51) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.65) by $0.14. The company had revenue of $7.88 million for the quarter, compared to analyst estimates of $0.08 million.

Several other research firms also recently commented on JANX. Wedbush reiterated an “outperform” rating and issued a $45.00 target price (down from $76.00) on shares of Janux Therapeutics in a research report on Tuesday, December 2nd. Wall Street Zen raised Janux Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, November 8th. Clear Str downgraded shares of Janux Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 20th. Bank of America reduced their target price on shares of Janux Therapeutics from $58.00 to $49.00 and set a “buy” rating on the stock in a report on Tuesday, December 2nd. Finally, Piper Sandler decreased their price target on shares of Janux Therapeutics from $42.00 to $30.00 and set an “overweight” rating for the company in a research report on Friday, January 16th. Eleven equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $56.91.

Janux Therapeutics Stock Down 2.6%

Shares of JANX stock opened at $13.97 on Thursday. The firm has a market capitalization of $849.80 million, a P/E ratio of -7.63 and a beta of 2.88. Janux Therapeutics has a twelve month low of $12.12 and a twelve month high of $35.34. The stock’s fifty day simple moving average is $13.69 and its 200 day simple moving average is $20.43.

Institutional Investors Weigh In On Janux Therapeutics

Large investors have recently added to or reduced their stakes in the business. Nano Cap New Millennium Growth Fund L P bought a new stake in shares of Janux Therapeutics in the fourth quarter valued at $34,000. Osaic Holdings Inc. grew its stake in shares of Janux Therapeutics by 704.6% during the 2nd quarter. Osaic Holdings Inc. now owns 3,468 shares of the company’s stock worth $80,000 after acquiring an additional 3,037 shares during the period. Virtus Investment Advisers LLC increased its holdings in Janux Therapeutics by 37.9% in the 2nd quarter. Virtus Investment Advisers LLC now owns 3,679 shares of the company’s stock worth $85,000 after acquiring an additional 1,011 shares during the last quarter. Caitong International Asset Management Co. Ltd purchased a new stake in Janux Therapeutics in the 4th quarter worth about $51,000. Finally, Tower Research Capital LLC TRC raised its stake in Janux Therapeutics by 175.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 3,928 shares of the company’s stock valued at $91,000 after acquiring an additional 2,502 shares during the period. Institutional investors and hedge funds own 75.39% of the company’s stock.

Insider Buying and Selling at Janux Therapeutics

In related news, insider Andrew Hollman Meyer sold 1,879 shares of the business’s stock in a transaction on Friday, January 2nd. The shares were sold at an average price of $13.73, for a total value of $25,798.67. Following the transaction, the insider owned 83,095 shares in the company, valued at $1,140,894.35. The trade was a 2.21% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO David Alan Campbell sold 8,072 shares of the stock in a transaction dated Friday, January 2nd. The stock was sold at an average price of $13.73, for a total value of $110,828.56. Following the sale, the chief executive officer owned 284,982 shares of the company’s stock, valued at approximately $3,912,802.86. The trade was a 2.75% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 19,033 shares of company stock valued at $261,323 over the last three months. 8.10% of the stock is currently owned by corporate insiders.

Key Janux Therapeutics News

Here are the key news stories impacting Janux Therapeutics this week:

• Positive Sentiment: HC Wainwright raised Q1–Q4 2026 EPS estimates and narrowed the expected FY2026 loss (now less negative), signaling better near-term operating outlook and execution. HC Wainwright raises near-term estimates
• Positive Sentiment: HC Wainwright reaffirmed a “Buy” rating and a $45 price target, implying substantial upside vs. the current share price if clinical and commercial progress meets expectations. HC Wainwright reiterates Buy/$45 PT
• Neutral Sentiment: Coverage roundup: a Globe and Mail piece includes Janux among healthcare companies discussed by analysts (broad market/sector context rather than company-specific new data). Analysts Offer Insights on Healthcare Companies
• Negative Sentiment: HC Wainwright cut several multi-year forecasts (FY2027–FY2029 and FY2028 in particular) — shifting some years to larger expected losses or pushing out profitability — which raises uncertainty about Janux’s longer-term revenue and margin trajectory. HC Wainwright lowers longer-term estimates

Janux Therapeutics Company Profile

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.